This Level II RCT tests whether adding an acellular human dermal matrix (GraftJacket) onlay to a standard single-row repair improves outcomes for large rotator cuff tears. It enrolled 42 patients with 2-tendon tears greater than 3 cm. Healing was judged by independent, blinded gadolinium-enhanced MRI and validated clinical scores.
The core teaching point: large, degenerate 2-tendon cuff tears fail because the biology is poor, not because the sutures are weak. Even ideal fixation cannot fix a hypovascular, low-cellularity tendon. This trial shows an acellular dermal matrix onlay addresses that biologic gap, raising intact-cuff rates from 40% to 85% on blinded MRI.
Contrast this with SIS porcine xenograft, which the paper reviews as ineffective (91% retear at 6 months) and associated with inflammatory reactions. Know that distinction for boards: human dermal allograft supports healing, SIS does not.
Weigh the evidence carefully. This is a Level II trial with 42 patients, short follow-up, industry funding, and no correlation between MRI healing and clinical scores. The structural benefit is real but the clinical magnitude and durability remain debated.
This Level II RCT tests whether adding an acellular human dermal matrix (GraftJacket) onlay to a standard single-row repair improves outcomes for large rotator cuff tears. It enrolled 42 patients with 2-tendon tears greater than 3 cm. Healing was judged by independent, blinded gadolinium-enhanced MRI and validated clinical scores.
The core teaching point: large, degenerate 2-tendon cuff tears fail because the biology is poor, not because the sutures are weak. Even ideal fixation cannot fix a hypovascular, low-cellularity tendon. This trial shows an acellular dermal matrix onlay addresses that biologic gap, raising intact-cuff rates from 40% to 85% on blinded MRI.
Contrast this with SIS porcine xenograft, which the paper reviews as ineffective (91% retear at 6 months) and associated with inflammatory reactions. Know that distinction for boards: human dermal allograft supports healing, SIS does not.
Weigh the evidence carefully. This is a Level II trial with 42 patients, short follow-up, industry funding, and no correlation between MRI healing and clinical scores. The structural benefit is real but the clinical magnitude and durability remain debated.